139 related articles for article (PubMed ID: 8836449)
1. Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits.
Takano S
Arch Int Pharmacodyn Ther; 1995; 330(3):297-308. PubMed ID: 8836449
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
Glusa E; Markwardt F
Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
[TBL] [Abstract][Full Text] [Related]
4. Involvement of 5-hydroxytryptamine in platelet aggregation in vivo in rats and guinea pigs.
Smith GM
Thromb Haemost; 1989 Jun; 61(3):463-7. PubMed ID: 2799759
[TBL] [Abstract][Full Text] [Related]
5. 5-hydroxytryptamine and platelet aggregation.
De Clerck FF; Herman AG
Fed Proc; 1983 Feb; 42(2):228-32. PubMed ID: 6822293
[TBL] [Abstract][Full Text] [Related]
6. ADP plays a key role in thrombogenesis in rats.
Maffrand JP; Bernat A; Delebassée D; Defreyn G; Cazenave JP; Gordon JL
Thromb Haemost; 1988 Apr; 59(2):225-30. PubMed ID: 3133809
[TBL] [Abstract][Full Text] [Related]
7. Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans.
Moerland M; Kemme M; Dijkmans A; Bergougnan L; Burggraaf J
J Cardiovasc Pharmacol; 2011 Dec; 58(6):575-80. PubMed ID: 21822145
[TBL] [Abstract][Full Text] [Related]
8. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin.
Qi R; Ozaki Y; Satoh K; Kurota K; Asazuma N; Yatomi Y; Kume S
Thromb Res; 1996 Jan; 81(1):43-54. PubMed ID: 8747519
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery.
Nishihira K; Yamashita A; Tanaka N; Kawamoto R; Imamura T; Yamamoto R; Eto T; Asada Y
J Thromb Haemost; 2006 Jan; 4(1):247-55. PubMed ID: 16409475
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
11. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
[TBL] [Abstract][Full Text] [Related]
12. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of ADP-induced aggregation by 5-HT in rabbit platelets.
Li BY; Bai Y; Li WH
Zhongguo Yao Li Xue Bao; 1998 Jan; 19(1):58-62. PubMed ID: 10375761
[TBL] [Abstract][Full Text] [Related]
14. [Modulating effects of adenosine on the process of human platelet activation].
Prokudin VIu; Melkova OM; Karaulov AV; Porodenko NV
Biull Eksp Biol Med; 1992 Jun; 113(6):606-8. PubMed ID: 1446028
[TBL] [Abstract][Full Text] [Related]
15. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
16. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
[TBL] [Abstract][Full Text] [Related]
17. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
[TBL] [Abstract][Full Text] [Related]
18. The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus.
Pietraszek MH; Takada Y; Taminato A; Yoshimi T; Watanabe I; Takada A
Thromb Res; 1993 Apr; 70(2):131-8. PubMed ID: 8322284
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
[TBL] [Abstract][Full Text] [Related]
20. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an in vitro study.
Felixsson E; Persson IA; Eriksson AC; Persson K
Phytother Res; 2010 Sep; 24(9):1297-301. PubMed ID: 20148408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
